[Treatment of post kidney transplantation erythrocytosis (PTE) with ACE inhibitors].

Abstract

BACKGROUND:

Post kidney transplantation erythrocytosis is a frequent complication in male subjects. In our experience, it occurs in approximately 20% of transplant patients receiving cyclosporine immunosuppression therapy.

METHODS:

Twenty-two patients with post kidney transplantation erythrocytosis were treated using ACE-inhibitors (lisinopril) at a dose of 2-5-5 mg/day for a mean period of 15 months. Owing to the onset of collateral effects, 27% of these patients requested the conversion of ACE into angiotensin II receptor antagonists (AII). Twenty out of 22 patients were male (90%).

RESULTS:

Treatment resulted in a 15% reduction of hematocrit values compared to basal levels, which remained stable over time. No collateral effects were recorded, either for the kidneys or in terms of hypotension.

CONCLUSIONS:

ACE-inhibitors (lisinopril) or alternatively the use of angiotensin II receptor antagonists, like Losartan, at low doses, is an effective and safe treatment for patients developing post-transplantation erythrocytosis (PTE).

• Authors: W Morale, C Puliatti, P Veroux, M Veroux, C Valvo, D Cappello, D Puliatti, L Francesco
• Journal: Minerva urologica e nefrologica = The Italian journal of urology and nephrology (Minerva Urol Nefrol) Vol. 54 Issue 2 Pg. 145-8 (Jun 2002) ISSN: 0393-2249 [Print] Italy
• Vernacular Title: Trattamento dell'eritrocitosi post-trapianto (PTE) renale con gli ACE-inibitori.
• PMID: 12070465 (Publication Type: English Abstract, Journal Article)

Chemical References

• Angiotensin Receptor Antagonists
• Angiotensin-Converting Enzyme Inhibitors
• Immunosuppressive Agents
• Cyclosporine
• Lisinopril
• Losartan

Topics

• Angiotensin Receptor Antagonists
• Angiotensin-Converting Enzyme Inhibitors (adverse effects, therapeutic use)
• Cyclosporine (adverse effects)
• Drug Evaluation
• Female
• Follow-Up Studies
• Hematocrit
• Humans
• Immunosuppressive Agents (adverse effects)
• Kidney Transplantation
• Lisinopril (adverse effects, therapeutic use)
• Losartan (therapeutic use)
• Male
• Polycythemia (chemically induced, drug therapy)
• Postoperative Complications (chemically induced, drug therapy)
• Retrospective Studies